Stockreport

MiNK Therapeutics Reports Q3 2025 Results and Accelerates iNKT Platform Toward Pivotal Development Across Oncology, Pulmonary Disease, and Transplantation [Yahoo! Finance]

MiNK Therapeutics, Inc.  (INKT) 
PDF GVHD trial launching through non-dilutive funding from NIH- and philanthropic grants Launching Phase 2+ trial in severe pulmonary disease in US population with FDA-va [Read more]